Umuti wa kanseri uherutse guhinduka muburyo butangaje; imwe mu majyambere yingenzi yabonetse hamwe nuburyo bwo kuvura immunotherapie kurwego rwa selire. B-selile Leukemia itandukanye na kanseri yamaraso isigaye kubera ibibazo byihariye nibisubizo byubuvuzi. Iyi ndwara, cyane cyane iterwa no kwiyongera kwa lymphocytes B mu maraso, bizatera uburyo bushya bwo gutekereza ku kurwanya indwara no kunoza umusaruro w’abarwayi. Ubushakashatsi burakomeje burakorwa kugirango hagaragazwe uruhare rushya rwa B-selile mu kuvura indwara zishingiye ku ndwara zishingiye ku ndwara zakozwe kugira ngo zikore ku buryo bushingiye ku ndwara. Pekin BIOOCUS Biotech Ltd ibereye imbere yiyi nzira y'ubwihindurize, ikora ubushakashatsi no guteza imbere immunotherapie selile, kandi ubundi igerageza kubusa gukemura ibibazo bya B-Cell Leukemia. Isosiyete ikora ibijyanye n’ibinyabuzima mu Bushinwa nayo yishimira kuba uruganda rw’agaciro rwose rufite ikigo cy’ubushakashatsi cyigenga, ikigo cya GMP, urubuga rwa CDMO, hamwe n’ikoranabuhanga ryohereza ikoranabuhanga. Amasezerano yacu yo kuvura B-Cell Leukemia arenze igipimo cyo kubaho; igera no gukora ubuvuzi burushijeho kuba bwiza kubarwayi, hamwe nuburyo bushya kandi bwihariye.